Fig. 1: Neutralization by sera from the first and second dose of the BNT162b2 mRNA vaccine against wild-type and B.1.1.7 spike mutant SARS-CoV-2-pseudotyped viruses.
From: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
a, Spike in the open conformation with a single erect RBD (Protein Data Bank (PDB): 6ZGG) is shown in the vertical view of the trimer axis. The locations of mutated residues are shown as red spheres, with deletions indicated in a dashed outline, and are labelled on the monomer with an erect RBD. b–g, The 50% serum neutralization titres of the first dose of the vaccine (b, c, n = 37), the second dose of the vaccine (d, e, n = 21) and convalescent sera (f, g, n = 27) against the wild-type (WT) spike protein and the spike protein of the variant B.1.1.7 (containing the N501Y, A570D, ΔH69/ΔV70, ΔY144, P681H, T716I, S982A and D1118H mutations). HS, human serum control. b, d, f, Mean fold changes in ID50 are indicated above the graphs. Data points of the same individual are connected by lines. Data are GMT ± s.d. and individual values of two independent experiments each with two technical repeats. Two-tailed Wilcoxon matched-pairs signed-rank test with no adjustment for multiple comparisons; **P < 0.01, ****P < 0.0001. The cut-off for 50% neutralization was set to 4.
